Wei Zhang, Shengdong Wang, Houfa Yin, Erman Chen, Deting Xue, Qiang Zheng, Xiang Gao, Zhijun Pan
Substantial evidence has demonstrated that the decreased osteogenic differentiation of bone mesenchymal stem cells (BMSCs) is closely related to bone metabolic diseases. Thus, it is very important to develop several potentially useful therapeutic agents to enhance BMSC osteogenesis. Flavonoids show promise in enhancing bone mass. Dihydromyricetin (DMY), a type of flavonoid, has not yet been investigated regarding its effects on BMSC osteogenesis. To investigate the effects of DMY on osteogenesis, human BMSCs were induced with or without DMY...
December 2016: Fundamental & Clinical Pharmacology